Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Myeloid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 7Burkitt Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 6Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 4Leukemia, Prolymphocytic 4Tumor Lysis Syndrome 3Neoplasms, Plasma Cell 3Myeloproliferative Disorders 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hyperuricemia 3Hodgkin Disease 3Congenital Abnormalities 3Primary Myelofibrosis 2Neoplasms 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Biphenotypic, Acute 2HIV Infections 2

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Allopurinol × Clear all
NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

NCT00276003 2010-01-07

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

University of New Mexico

Phase 2 Completed
22 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡